Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie. 14. November 2022 Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al., 2022. Oncol Res Treat 2021;44:1–335 Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315. Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al. 2022. Annals of Oncology. 2022 Sep;33(Supplement 7):S988. Download… Weiterlesen Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315. Gröschel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, et al. Oncol Res Treat. 2022;45(suppl 1)(Abstract 135):148. Download… Weiterlesen